Monte Rosa Therapeutics, Inc. Share Price & Technical Analysis
GLUE · $19.20 (+2.07%)
Healthcare / Biotechnology
$19.20
+2.07%
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment …
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-1% return in May, 8% avg return in past 3 year May month.
26% return in 2026, 72% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 31% | -13% | -4% | 14% | -1% | – | – | – | – | – | – | – | 26% |
| 25 | -4% | -14% | -16% | 7% | -14% | 7% | 9% | 0% | 54% | 74% | 28% | -2% | 128% |
| 24 | -5% | 19% | 8% | -25% | -24% | -7% | 18% | 38% | -13% | 63% | 24% | -33% | 62% |
| 23 | -11% | -16% | 28% | -43% | 61% | -8% | 6% | -17% | -19% | -29% | -9% | 84% | 27% |
| 22 | -38% | 13% | -2% | -22% | -29% | 26% | -7% | -11% | 4% | 11% | -9% | -11% | -76% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.62B
P/E ratio
—
52W high
$25.77
52W low
$3.90
Volume
6,59,478
Beta
1.62
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Monte Rosa Therapeutics, Inc. share price today?
- Monte Rosa Therapeutics, Inc. (GLUE) last traded around $19.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GLUE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GLUE. Download the app for real-time alerts.
- How can I analyze Monte Rosa Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.